Literature DB >> 3458526

Cytogenetic characterization of putative human myeloblastic leukemia cell lines (ML-1, -2, and -3): origin of the cells.

K Ohyashiki, J H Ohyashiki, A A Sandberg.   

Abstract

Cytogenetic studies were performed on ML cell lines (ML-1, -2, and -3), as well as on the leukemic cells of a patient from whom the ML cells were derived. The ML-1 cell line showed numerical and structural cytogenetic changes, i.e., -Y, 1p-, 6q-, 11q-, +12, +13q+, 14q-, and 17q-. The ML-2 cell line had two copies of the 13q+, whereas the ML-3 cells contained three clones, i.e., 47,X,-Y,1p-,6q-,11q-,+12,+13q+, 48,X,-Y,1p-,6q-,+6q-,11q-,+12,+13q+, and 49,X,-Y,1p-,6q-,+6q-, 11q-,+12,+13q+,+13q+. The neoplastic cells, when the patient was diagnosed as having T-cell malignant lymphoma (Stage IV), had the 11q- and 13q+. The leukemic cells in a subsequent acute myeloid leukemia phase of this patient contained structural (1p- and 6q-) and numerical (+12, -Y and +2D-group chromosomes: two 13q+) changes in addition to the 11q-. These findings suggest that the acute myeloid leukemic cells of this patient probably originated from the neoplastic cells of the preceding T-cell lymphoma, and that the chromosome changes originally seen in the lymphoma cells were preserved in the established ML cell lines, though the cells of these lines had myeloid characteristics.

Entities:  

Mesh:

Year:  1986        PMID: 3458526

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.

Authors:  R A Fleck; S Romero-Steiner; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

2.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.

Authors:  K M Kozopas; T Yang; H L Buchan; P Zhou; R W Craig
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

3.  Lineage-restricted expression of homeobox-containing genes in human hematopoietic cell lines.

Authors:  W F Shen; C Largman; P Lowney; J C Corral; K Detmer; C A Hauser; T A Simonitch; F M Hack; H J Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

4.  MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.

Authors:  Yufei Chen; Konstantinos Anastassiadis; Andrea Kranz; A Francis Stewart; Kathrin Arndt; Claudia Waskow; Akihiko Yokoyama; Kenneth Jones; Tobias Neff; Yoo Lee; Patricia Ernst
Journal:  Cancer Cell       Date:  2017-06-12       Impact factor: 31.743

5.  Protein Tyrosine Phosphatase Gamma (PTPgamma) is a Novel Leukocyte Marker Highly Expressed by CD34 Precursors.

Authors:  Andrea Mafficini; Marzia Vezzalini; Loris Zamai; Laura Galeotti; Gabriella Bergamini; Marco Della Peruta; Paola Melotti; Claudio Sorio
Journal:  Biomark Insights       Date:  2007-05-31

6.  Localization of gelsolin proximal to ABL on chromosome 9.

Authors:  D J Kwiatkowski; C A Westbrook; G A Bruns; C C Morton
Journal:  Am J Hum Genet       Date:  1988-04       Impact factor: 11.025

7.  A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.

Authors:  Andrei V Krivtsov; Kathryn Evans; Jayant Y Gadrey; Benjamin K Eschle; Charlie Hatton; Hannah J Uckelmann; Kenneth N Ross; Florian Perner; Sarah N Olsen; Tara Pritchard; Lisa McDermott; Connor D Jones; Duohui Jing; Ali Braytee; Diego Chacon; Eric Earley; Brian M McKeever; David Claremon; Andrew J Gifford; Heather J Lee; Beverly A Teicher; John E Pimanda; Dominik Beck; Jennifer A Perry; Malcolm A Smith; Gerard M McGeehan; Richard B Lock; Scott A Armstrong
Journal:  Cancer Cell       Date:  2019-12-09       Impact factor: 31.743

8.  Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.

Authors:  Kathryn Hall; Karen J Scott; Ailsa Rose; Michael Desborough; Kevin Harrington; Hardev Pandha; Christopher Parrish; Richard Vile; Matt Coffey; David Bowen; Fiona Errington-Mais; Alan A Melcher
Journal:  Biores Open Access       Date:  2012-01

9.  Targeting AML through DR4 with a novel variant of rhTRAIL.

Authors:  Eva Szegezdi; Carlos R Reis; Almer M van der Sloot; Alessandro Natoni; Aoife O'Reilly; Janice Reeve; Robbert H Cool; Michael O'Dwyer; Steven Knapper; Luis Serrano; Wim J Quax; Afshin Samali
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

10.  RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.

Authors:  Adam C Wilkinson; Erica Ballabio; Huimin Geng; Phillip North; Marta Tapia; Jon Kerry; Debabrata Biswas; Robert G Roeder; C David Allis; Ari Melnick; Marella F T R de Bruijn; Thomas A Milne
Journal:  Cell Rep       Date:  2013-01-24       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.